Many pharmacies and health plans had plenty of the new Pfizer boosters to offer but not Moderna.
If you want the new COVID-19 booster that protects against the latest circulating omicron variants, you have lots of options for appointments, except if you have your heart set on Moderna.
But on the Bay Area Vaccine Hunters Facebook group this week, members pleaded for tips about available Moderna doses and groused about cancellations. For those who just have to have the Moderna shot, bivalent booster appointments are available if you look around. One place that wasn’t hurting for supplies was Santa Clara County’s health system where on Thursday online appointments for the Moderna bivalent booster were plentiful next week.
Moderna’s news office had no response Thursday to questions about Bay Area booster shortages, and the company hasn’t issued recent statements indicating production or distribution issues. Its website directs those seeking the shots to the federal government’s online scheduler. But it indicates availability at several pharmacies that don’t actually have the shots now.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer starts late-stage trial of mRNA-based flu vaccinePfizer Inc said on Wednesday it had started a late-stage U.S. trial of an influenza vaccine involving 25,000 patients, among the first such studies for a messenger RNA flu shot.
Lire la suite »
Pfizer begins late-stage human study on an mRNA flu shotDrugmaker Pfizer said Wednesday it has begun a late-stage human trial of an influenza vaccine that uses the pioneering messenger-RNA deployed widely for the coronavirus.
Lire la suite »
Flu Season Is Coming. mRNA Flu Shots Aren't Far BehindModerna and Pfizer are testing mRNA flu shots that target the strains most likely to circulate during the 2022 flu season
Lire la suite »
U.S. drug price cap hurts Big Pharma twice overPresident Biden’s plan to curb medicine bills could cost drugmakers like Pfizer or GSK $29 bln a year in lost sales. To cope, companies may focus on blockbuster therapies, and shun niche treatments. More competition in hot areas like cancer may mean lower prices and poor returns.
Lire la suite »
Want the new COVID-19 vaccine booster? No problem, unless it’s got to be ModernaMany pharmacies and health plans had plenty of the new Pfizer boosters to offer but not Moderna.
Lire la suite »